Christopher Baker, MD
Radiation Oncology · Bozeman, MTNPI 1609223932
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,935 of the $2,397 with a category attached, or 80.7%. It is spread thinly across 29 manufacturers, the largest accounting for just 21.6% — the pattern of someone who eats at a lot of different presentations.
Across 92 payments — averaging $26.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Philips North America LLC$518
- Johnson & Johnson$325
- AstraZeneca$287
- Merck$200
- Siemens Medical Solutions USA, Inc.$154
- Regeneron Healthcare Solutions, Inc.$103
- plus $810 from 23 others
What the payments were for
- Travel & lodging$46319%
- Food & beverage$1,93581%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Philips North America LLC | 4 | $518 |
| Johnson & Johnson | 19 | $325 |
| AstraZeneca | 13 | $287 |
| Merck | 9 | $200 |
| Siemens Medical Solutions USA, Inc. | 3 | $154 |
| Regeneron Healthcare Solutions, Inc. | 4 | $103 |
| Genentech USA, Inc. | 4 | $84 |
| Myriad Genetic Laboratories, Inc. | 4 | $80 |
| Lilly USA, LLC | 4 | $75 |
| Stemline Therapeutics Inc. | 3 | $73 |
| Daiichi Sankyo Inc. | 2 | $72 |
| Jazz Pharmaceuticals Inc. | 2 | $61 |
| Incyte Corporation | 2 | $38 |
| Novartis | 2 | $36 |
| Novocure Inc. | 2 | $36 |
| Pfizer | 2 | $36 |
| Array Biopharma Inc | 1 | $22 |
| Pharmaessentia USA Corporation | 1 | $21 |
| Blueprint Medicines Corporation | 1 | $18 |
| AbbVie | 1 | $18 |
| Aadi Bioscience, Inc. | 1 | $18 |
| ADC Therapeutics America, Inc. | 1 | $18 |
| Myovant Sciences Inc. | 1 | $17 |
| Telix Pharmaceuticals | 1 | $16 |
| Bristol Myers Squibb | 1 | $16 |
| Exelixis Inc. | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Acceleron Pharma, Inc. | 1 | $12 |
| GSK | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few radiation oncology providers in Montanato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 29 | $174 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Bozeman
- Berna DemalignonGreat Falls$5K
- Carolyn RutterGreat Falls$2K
- Jeffrey EshlemanKalispell$1K
- Joseph ClydeGreat Falls$1K
- Justin LinamKalispell$687
- Ralf KiehlSidney$538
- Trent MihalickBillings$352
- John SchallenkampBillings$274
- Michelle ProperMissoula$245
- Gordon StillieKalispell$231
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.